In this issue Dr. Neil Bressler, of the Johns Hopkins School of Medicine is joined by his colleagues, Dr. Michael Elman of the Johns Hopkins School of Medicine, Dr. John Wells of the Palmetto Retina Center. They will discuss findings from the recently completed NIH CER trial on aflibercept, bevacizumab, and ranibizumab for DME treatment.